See more : Northamerican Energy Group Corporation (NNYR) Income Statement Analysis – Financial Results
Complete financial analysis of Healios K.K. (4593.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Healios K.K., a leading company in the Biotechnology industry within the Healthcare sector.
- Thachang Green Energy Public Company Limited (TGE.BK) Income Statement Analysis – Financial Results
- Vibra Energia S.A. (BRDT3.SA) Income Statement Analysis – Financial Results
- Virco Mfg. Corporation (VIRC) Income Statement Analysis – Financial Results
- BayCurrent Consulting, Inc. (BYCRF) Income Statement Analysis – Financial Results
- Astral Limited (ASTRAL.NS) Income Statement Analysis – Financial Results
Healios K.K. (4593.T)
About Healios K.K.
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 121.00M | 90.00M | 41.00M | 27.00M | 89.00M | 0.00 | 27.67M | 77.64M | 98.17M | 280.00M |
| Cost of Revenue | 13.00M | 0.00 | 0.00 | 0.00 | 69.00M | 78.00M | 3.32M | 9.15M | 9.39M | 49.23M |
| Gross Profit | 108.00M | 90.00M | 41.00M | 27.00M | 20.00M | -78.00M | 24.35M | 68.50M | 88.78M | 230.77M |
| Gross Profit Ratio | 89.26% | 100.00% | 100.00% | 100.00% | 22.47% | 0.00% | 88.00% | 88.22% | 90.43% | 82.42% |
| Research & Development | 2.30B | 3.81B | 3.70B | 2.99B | 3.22B | 4.27B | 1.73B | 2.96B | 629.10M | 327.06M |
| General & Administrative | 1.18B | 1.45B | 1.72B | 1.24B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.18B | 1.45B | 1.72B | 1.24B | 1.01B | 716.00M | 541.88M | 447.03M | 356.62M | 804.00M |
| Other Expenses | 0.00 | 12.00M | 3.00M | -14.00M | 1.05B | 794.00M | 2.87M | 116.84M | 137.69M | 99.18M |
| Operating Expenses | 3.49B | 5.27B | 5.43B | 4.21B | 4.27B | 5.06B | 2.37B | 3.58B | 1.15B | 799.06M |
| Cost & Expenses | 3.50B | 5.27B | 5.43B | 4.21B | 4.27B | 5.06B | 2.38B | 3.59B | 1.16B | 848.29M |
| Interest Income | 456.00M | 346.00M | 1.73B | 1.00M | 1.00M | 0.00 | -54.14M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 704.00M | 500.00M | 802.00M | 1.18B | 43.00M | 28.00M | 26.86M | 26.01M | 0.00 | 1.14M |
| Depreciation & Amortization | 224.00M | 386.00M | 262.00M | 229.00M | 141.00M | 78.00M | 100.32M | 169.31M | 128.07M | 98.88M |
| EBITDA | -2.70B | -4.52B | -3.61B | -3.97B | -4.17B | -5.01B | -1.64B | -3.23B | -932.35M | -356.03M |
| EBITDA Ratio | -2,229.75% | -4,937.78% | -8,287.80% | -14,692.59% | -4,943.82% | 0.00% | -8,360.69% | -4,196.14% | -979.19% | -167.65% |
| Operating Income | -3.38B | -5.18B | -5.38B | -4.18B | -4.27B | -5.06B | -2.35B | -3.51B | -1.06B | -568.30M |
| Operating Income Ratio | -2,792.56% | -5,754.44% | -13,131.71% | -15,496.30% | -4,798.88% | 0.00% | -8,487.70% | -4,517.60% | -1,080.22% | -202.97% |
| Total Other Income/Expenses | -247.00M | -151.00M | 923.00M | -1.18B | -250.00M | -28.00M | 576.45M | 80.72M | 102.29M | 97.73M |
| Income Before Tax | -3.63B | -5.33B | -4.46B | -5.38B | -4.40B | -5.09B | -1.77B | -3.43B | -958.13M | -470.56M |
| Income Before Tax Ratio | -2,996.69% | -5,922.22% | -10,882.93% | -19,918.52% | -4,947.19% | 0.00% | -6,403.35% | -4,413.63% | -976.02% | -168.06% |
| Income Tax Expense | 187.00M | -160.00M | 450.00M | 135.00M | 6.00M | 5.00M | 5.10M | 6.81M | -25.00K | 6.69M |
| Net Income | -3.82B | -5.17B | -4.91B | -5.51B | -4.41B | -5.10B | -1.78B | -3.43B | -958.10M | -477.26M |
| Net Income Ratio | -3,159.50% | -5,744.44% | -11,980.49% | -20,418.52% | -4,953.93% | 0.00% | -6,421.79% | -4,422.40% | -975.99% | -170.45% |
| EPS | -56.22 | -90.69 | -93.40 | -107.21 | -87.94 | -103.52 | -39.73 | -84.33 | -25.60 | -14.17 |
| EPS Diluted | -56.22 | -90.69 | -93.40 | -107.21 | -87.94 | -103.52 | -39.73 | -84.33 | -25.60 | -12.01 |
| Weighted Avg Shares Out | 68.00M | 57.01M | 52.59M | 51.42M | 50.14M | 49.24M | 44.72M | 40.72M | 37.42M | 33.68M |
| Weighted Avg Shares Out (Dil) | 68.00M | 57.01M | 52.59M | 51.42M | 50.14M | 49.24M | 44.72M | 40.72M | 37.42M | 39.74M |
Source: https://incomestatements.info
Category: Stock Reports